News
Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical trial participants who took tirzepatide,
According to a study funded by Eli Lilly, the trial revealed that participants taking tirzepatide, the drug sold as ...
A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...
Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.
While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...
A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback